A vaccine administered during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A significant recent study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the timeframe when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation safeguards vulnerable infants
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can range from causing mild, cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of serious RSV infections: “In babies with bad infections you can see their chest and lungs working hard, as they attempt to draw enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”
The pregnancy vaccine works by stimulating the mother’s immune system to generate defence proteins, which are then passed to the foetus through the placenta. This mother-derived protection offers newborns with immediate protection from the moment of birth, exactly when they are most vulnerable to RSV. The new study shows that protection reaches approximately 85% when the vaccine is administered four weeks or more before delivery. Even briefer gaps between vaccination and birth can still provide meaningful protection, with evidence suggesting that a two-week gap is adequate to shield babies born slightly early. Dr Watson recommends pregnant women to have the vaccine at the recommended time, whilst noting that protection remains possible even if given later in the third trimester.
- Nearly 85 per cent protection when immunised four weeks before birth
- Maternal antibodies transferred through the placenta safeguard newborns from day one
- Coverage achievable with two-week gap before early delivery
- Vaccination in third trimester still offers meaningful infant protection
Compelling evidence from recent research
The performance of the pregnancy RSV vaccine has been demonstrated through a thorough investigation carried out throughout England, examining data from nearly 300,000 babies born between September 2024 and March 2025. This accounts for approximately nine out of ten of all births during that half-year window, providing strong and reliable data of the vaccine’s practical effectiveness. The study’s findings have been supported by the UK Health Security Agency as showing robust protection for newborns during their most critical early weeks. The breadth of this investigation provides healthcare professionals and prospective parents with assurance in the vaccine’s established performance across diverse populations and circumstances.
The results paint a notable picture of the vaccine’s protective effectiveness. More than 4,500 babies were treated in hospital with RSV throughout the study period, with the vast majority being infants whose mothers had not received the vaccination. This stark contrast highlights the vaccine’s critical role in preventing serious illness in newborns. The reduction in hospital admissions above 80 per cent represents a major public health success, helping to prevent thousands of infants from experiencing the distressing and potentially serious symptoms linked to severe RSV infection. These findings strengthen the importance of the vaccination programme launched in the UK in 2024.
Research approach and coverage
The research analysed birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were in a position to determine direct comparisons of RSV infection levels and hospitalisations. The substantial sample size and comprehensive nature of the data gathering ensured that findings were statistically robust and indicative of the general population, rather than isolated cases or small subgroups.
The study specifically tracked hospital admissions for RSV among infants born to mothers who had been given the vaccine at varying intervals before delivery. This allowed researchers to establish the least amount of time between vaccination and birth for best possible protection, as well as to determine whether protection stayed significant with shorter intervals. The methodology assessed actual clinical results rather than experimental conditions, providing tangible evidence of how the vaccine performs when delivered across diverse clinical settings and patient circumstances throughout the final three months of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Comprehending RSV and its dangers
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity varying dramatically from minor cold-type symptoms to serious, potentially fatal chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on children’s wards and newborn care units during busier periods.
The infection causes deep inflammation in the lungs and airways, making it dangerously difficult for vulnerable newborns to breathe and feed properly. Parents commonly see their babies fighting for breath, their chests rising whilst they work to get enough air into their weakened respiratory system. Whilst most infants recover with palliative treatment, a small but significant proportion perish from respiratory syncytial virus complications annually, making vaccination as prevention a essential public health objective for safeguarding the most vulnerable and youngest people in our communities.
- RSV triggers lung inflammation, causing serious respiratory problems in infants
- Nearly 50% of infants acquire the infection during their first few months alive
- Symptoms span from minor cold-like symptoms to life-threatening chest infections requiring hospitalisation
- Over 20,000 UK infants require serious hospital care for RSV each year
- Small numbers of babies die from RSV related complications each year in the UK
Uptake rates and professional guidance
Since the RSV vaccine programme launched in 2024, health officials have highlighted the importance of pregnant women getting their jab at the ideal time for maximum protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has emphasised that the timing is essential for guaranteeing newborns receive the strongest possible immunity from birth. Whilst the research shows that vaccination at least four weeks before delivery offers approximately 85% protection, experts advise women to receive their vaccine as early as possible from 28 weeks of pregnancy onwards to maximise the antibodies transferred to their babies via the placenta.
The guidance from public health bodies remains clear: pregnant women should make a priority of getting vaccinated during their third trimester, even if circumstances mean they cannot receive the jab at the best timing. Dr Watson has reassured expectant mothers that protection is still achievable with shorter intervals between immunisation and delivery, including even a fourteen-day window for those delivering slightly early. This flexible approach acknowledges the realities of pregnancy and childbirth whilst maintaining strong protection for vulnerable newborns during their earliest and most vulnerable period when RSV represents the highest danger of serious illness.
Regional differences in immunisation
Whilst the RSV vaccine programme has been implemented across England, uptake rates and implementation timelines have varied across various areas and NHS trusts. Some areas have attained greater immunisation rates among qualifying expectant mothers, whilst others continue working to boost understanding and availability of the jab. These regional differences demonstrate differences across healthcare infrastructure, engagement approaches, and local engagement efforts, though the overall statistics demonstrates robust and reliable protection irrespective of geographical location.
- NHS trusts deploying varied communication campaigns to reach women during pregnancy
- Regional disparities in vaccination coverage levels across England require targeted improvement
- Regional health providers tailoring initiatives to suit community needs and circumstances
Real-world impact and parental perspectives
The vaccine’s remarkable effectiveness delivers real advantages for families across the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV before the rollout of this preventative solution, the 80% reduction in admissions means thousands of infants protected against serious illness. Parents no more face the distressing scenario of watching their newborns labour to breathe or labour to feed, symptoms that characterise severe RSV infections. The vaccine has fundamentally shifted the terrain of neonatal respiratory health, offering expectant mothers a proactive tool to protect their most at-risk babies during those crucial first weeks.
For families like that of Malachi, whose acute RSV infection led to devastating brain damage, the vaccine’s availability carries profound emotional significance. His mother’s advocacy for the jab highlights the life-altering consequences that vaccine-preventable disease can have on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story strikes a chord with parents now offered protection. The knowledge that such serious complications—hospitalisation, oxygen dependency, neurological damage—are now largely preventable has given considerable reassurance to expectant mothers in their late pregnancy, changing what was once an inevitable seasonal threat into a manageable risk.